‘Case of the Month’ from the University of Verona, Italy—navigating the medical and surgical challenges of urinary bladder paraganglioma: insights from a clinical case

IF 4.4 2区 医学 Q1 UROLOGY & NEPHROLOGY BJU International Pub Date : 2024-11-16 DOI:10.1111/bju.16596
Lorenzo Pierangelo Treccani, Francesco Artoni, Claudio Brancelli, Alessandro Veccia, Mirko D'Onofrio, Isabella Pichiri, Matteo Brunelli, Riccardo Giuseppe Bertolo, Alessandro Antonelli
{"title":"‘Case of the Month’ from the University of Verona, Italy—navigating the medical and surgical challenges of urinary bladder paraganglioma: insights from a clinical case","authors":"Lorenzo Pierangelo Treccani,&nbsp;Francesco Artoni,&nbsp;Claudio Brancelli,&nbsp;Alessandro Veccia,&nbsp;Mirko D'Onofrio,&nbsp;Isabella Pichiri,&nbsp;Matteo Brunelli,&nbsp;Riccardo Giuseppe Bertolo,&nbsp;Alessandro Antonelli","doi":"10.1111/bju.16596","DOIUrl":null,"url":null,"abstract":"<p>A 44-year-old woman came to us with a history of two paravesical masses, monitored via radiological imaging for 10 years.</p><p>The patient's medical history revealed multiple episodes of pulmonary embolism after orthopaedic surgery since the age of 22 years. The patient tested negative for any form of coagulopathy. To note, the patient had developed hypertension at a young age, necessitating polypharmacotherapy, accompanied by additional adrenergic symptoms such as flushing, limb tremors, panic attacks, and palpitations.</p><p>The first diagnosis of bladder masses occurred incidentally during a routine abdominal ultrasonography scan performed in the setting of an episode of suspected cystitis. Subsequent cystoscopy revealed two bulges on the left lateral wall, covered by normal bladder mucosa. The patient was followed up with repeated ultrasonography scans; neither clinical nor radiological alterations were noted until the patient reported an episode of gross haematuria in 2022. Subsequent abdominal CT scan and MRI (Figs 1 and S1) revealed a solid mass, 4.5 cm in maximum size, located near the posterior left bladder wall (in contact with but not infiltrating, the cervix) and another mass measuring 2.1 cm near the left lateral bladder wall.</p><p>Operative cystoscopy with biopsy was performed, which caused a hypertensive crisis complicated by acute pulmonary oedema, which required intubation and admission into the intensive care unit. The biopsy specimen's final pathology examination confirmed a bladder paraganglioma.</p><p>Further investigations during the hospital stay included a thorough cardiological evaluation (echocardiography, coronary CT-angiography), which suggested an atypical Takotsubo syndrome.</p><p>Takotsubo syndrome, also known as stress cardiomyopathy or ‘broken heart syndrome’, is a temporary heart condition that often mimics the symptoms of a heart attack. It is typically triggered by severe emotional or physical stress. The syndrome gets its name from the Japanese word ‘<i>takotsubo</i>’, which means ‘octopus pot’, due to the distinctive shape of the left ventricle seen in imaging tests during the condition [<span>1</span>].</p><p>Blood tests (serum chromogranin A, metadrenalines, and normetadrenaline) and urine analysis (urinary metadrenaline and normetadrenaline) revealed elevated levels of chromogranin A and normetadrenaline, while metadrenaline levels remained normal. A whole-body CT scan excluded distant metastases. Positron emission tomography (PET)/CT using gallium-tetraazacyclododecane tetraacetic acid (<sup>68</sup>Ga-DOTA)-conjugated somatostatin receptor–targeting peptide and <sup>18</sup>F-dihydroxyphenylalanine (DOPA) revealed hyper-fixation at the level of the masses, along with two small ileal foci and a right breast nodule (Fig. 2). These extravesical localisations were excluded from being metastatic. Genetic evaluation revealed a succinate dehydrogenase B subunit (<i>SDHB</i>) mutation linked to familial paraganglioma (paraganglioma type PGL4) [<span>2</span>].</p><p>After a careful multidisciplinary evaluation, given the masses’ size and the patient's age, the patient was counselled for bladder-sparing robot-assisted laparoscopic surgery (summarised in Video S1).</p><p>Prior to the operation, the patient first received alpha-blockade, followed by beta-blockade, and underwent aggressive intravenous fluid resuscitation while being treated in the endocrinology department. The surgery began by placing a left ureteric single-J stent in a retrograde fashion during cystoscopy. The robot-assisted laparoscopic phase started with incising the peritoneum at the level of the vesico-uterine pouch. The bigger mass was identified: its pedicle was first isolated, clipped, and divided. Only after controlling the pedicle was the dissection of the mass carried out. Notwithstanding the additional care, during the dissection of the main mass, a hypertensive crisis occurred (270/150 mmHg) with initial pulmonary oedema. The surgical procedure had to be paused, and the robot had to be undocked for ~10 min to allow for intensive care manoeuvres. The patient was positioned in an anti-Trendelenburg position. Beta-blockers and sodium nitroprusside were administered. The initial response was severe hypotension; however, normal blood pressure values were achieved only after the titration of the nitrate. In the case of nitrates, the titration involves starting with a low dose and gradually increasing it based on the patient's response regarding blood pressure, heart rate, and symptoms until the desired effect is achieved.</p><p>Once haemodynamic stability was achieved, the robotic part continued with the completion of the excision of the bigger mass, performed by a combination of extra- and transvesical approaches.</p><p>The second smaller mass was identified during the transvesical approach: first, the pedicle was secured. Second, the mass was excised with an extravesical approach. During the excision of the smaller mass, no intraoperative anaesthesiological adverse events occurred. The bladder defect was sutured in a double-layer fashion.</p><p>The postoperative course was uneventful. A drain and a Foley catheter were kept <i>in situ</i> for 2 and 10 days, respectively; the ureteric stent was removed after 7 days.</p><p>The pathological and immunohistochemical examination revealed a well-differentiated tumour, showing the typical cell-nests, synaptophysin, and chromogranin positive, suggesting paraganglioma (Fig. 3). Genetic analysis revealed mutations of <i>SDHB</i>, which are associated with an aggressive clinical presentation of paraganglioma (and pheochromocytoma).</p><p>Urinary bladder paraganglioma is rare, accounting for 0.05% of all bladder neoplasms. Paraganglioma is the denomination of any extra-adrenal pheochromocytoma. It is estimated that ~10% of all pheochromocytomas are extra-adrenal, and ~10% of these occur within the bladder wall. The tumour originates from the chromaffin tissues of the sympathetic nervous system located in the detrusor muscle of the urinary bladder; most commonly, they are located at the dome or the trigone. Paragangliomas can occur at any age, but the mean age at diagnosis is 43 years [<span>3</span>].</p><p>They are typically benign, but a variable percentage of cases can be malignant, mostly when associated with hereditary syndromes such as the <i>SDH</i> mutation (familiar paraganglioma syndromes). Malignancy is associated with younger age, larger and multiple masses, and metastases [<span>3</span>].</p><p>Signs and symptoms depend on whether the tumour is functional or non-functional. Functional tumours secrete catecholamines (adrenaline and noradrenaline), causing a variety of presenting symptoms (hypertensive crises, headache, palpitations, hot flushes, and sweating). These could also be present only when provoked by micturition (micturition syncope), defecation, sexual activity, ejaculation, or bladder/urethral instrumentation. The most common bladder-specific sign is painless haematuria, although it is non-specific. Biochemistry plays a key role in functional tumours: plasma and urine catecholamines and metadrenalines (more sensitive and specific) levels are usually elevated. Chromogranin A is also often elevated [<span>3</span>].</p><p>The primary tumour is usually diagnosed through cross-sectional imaging (either CT or MRI): common findings at MRI are a well-circumscribed round vascularised lesion that is hyperintense in T2 (‘lightbulb sign’). The best PET/CT imaging for diagnosing paragangliomas is typically <sup>68</sup>Ga-DOTA-conjugated somatostatin receptor-targeting peptide. This imaging technique uses gallium-68 labelled with DOTA-Tyr3-octreotate, a somatostatin analogue. It targets somatostatin receptors, often overexpressed in neuroendocrine tumours, including paragangliomas. While <sup>68</sup>Ga-DOTA PET/CT is highly regarded, other imaging techniques such as <sup>18</sup>F-fluorodeoxyglucose (FDG) PET/CT and <sup>131</sup>I-metaiodobenzylguanidine (MIBG) scintigraphy may still be used in specific scenarios: <sup>18</sup>F-FDG PET/CT is useful for paragangliomas that do not express somatostatin receptors; however, it is less effective for small, indolent tumours; <sup>131</sup>I-MIBG scintigraphy is primarily indicated for pheochromocytomas, but can also be used for paragangliomas that uptake MIBG. Unfortunately, it may miss non-functioning paragangliomas or those not taking up MIBG [<span>4</span>].</p><p>Cystoscopy, when performed, shows normal mucosa and an underlying mass bulging it. Transurethral manipulation and biopsy of functional paragangliomas could lead to potentially life-threatening cardiac events due to massive catecholamine release. This was the case of the first interventional cystoscopy performed at another institution before the patient came to us.</p><p>For the same reason, an endoscopic, transurethral approach as a treatment option should be avoided. As such, it often leads to incomplete resection and a high risk of perioperative cardiac events, particularly when a correct histopathological or clinical diagnosis has yet to be made [<span>5</span>]. Moreover, the endoscopic approach lacks the control of the vascular pedicle of the mass that a surgical approach (either open, laparoscopic, or robot-assisted) guarantees.</p><p>For these medical reasons, preoperative care is fundamental. About 2 weeks before surgery, alpha-blockade should be started, preferably with an irreversible alpha-blocker such as phenoxybenzamine. This molecule irreversibly binds to the alpha receptors, rendering any potential intraoperative catecholamine release from tumour manipulation ‘harmless’, as it would require <i>de novo</i> synthesis of alpha receptors for the catecholamines to exert their effect. Beta-blockade should be introduced (mainly to treat side effects from alpha-blockade) only after reaching the appropriate alpha-blockade. Otherwise, it would increase the affinity of catecholamines for the α<sub>1</sub> receptors. Finally, 1–2 days before surgery, aggressive intravenous hydration to restore the intravascular volume should be initiated to avoid postoperative severe hypotension given the prolonged effect of alpha-blockade [<span>6</span>].</p><p>After proper preparation, surgical excision is the mainstay treatment because paraganglioma is chemo-radioresistant. A radical excision of the mass should be performed whenever feasible. This is usually achieved through a partial cystectomy. Indeed, the bladder mucosa at the base of the mass should always be removed. In selected cases (large masses, metastases, suspected malignancy), radical cystectomy can be indicated. Pelvic lymph node dissection should be performed when a radical cystectomy is indicated, although there is not sufficient evidence supporting this choice [<span>7</span>].</p><p>Histopathological examination shows polygonal cells arranged in a nested fashion (‘Zellballen’), surrounded by a fibrovascular matrix [<span>8</span>]. This pattern could trick the pathologist's eye and be confused with a nested variant of TCC. Immunohistochemistry shows positivity for chromogranin A, synaptophysin, and GATA binding protein 3 (GATA-3); cytokeratins are negative [<span>3</span>].</p><p>A summation section of the most relevant diagnostic evaluation, medical, and anaesthesiological information is provided as Data S1 at the reader's convenience.</p><p>In summary, our case report underscores that not all patients with gross haematuria should be treated equally. Specifically, the presence of a mass bulging on the bladder mucosa in a younger patient with adrenergic symptoms should suggest at least considering the possibility of a bladder paraganglioma. This could help reach a correct diagnosis before any invasive manoeuvre is performed. Moreover, it would avoid potentially fatal perioperative adverse events or incomplete excision of the mass typical of transurethral resections performed before confirming paraganglioma diagnosis [<span>9</span>].</p><p>Once surgical removal of a diagnosed bladder paraganglioma is indicated, despite cautious premedication of patients, the experience of the surgeon, and necessary surgical precautions in handling these formations before controlling their vascular pedicles, it must be remembered that surgery is not straightforward when such paragangliomas are functional. This holds true both from a technical standpoint and, more importantly, considering its potential anaesthesiological implications.</p><p>The authors have no conflict of interest.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"135 5","pages":"743-747"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.16596","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJU International","FirstCategoryId":"3","ListUrlMain":"https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.16596","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

A 44-year-old woman came to us with a history of two paravesical masses, monitored via radiological imaging for 10 years.

The patient's medical history revealed multiple episodes of pulmonary embolism after orthopaedic surgery since the age of 22 years. The patient tested negative for any form of coagulopathy. To note, the patient had developed hypertension at a young age, necessitating polypharmacotherapy, accompanied by additional adrenergic symptoms such as flushing, limb tremors, panic attacks, and palpitations.

The first diagnosis of bladder masses occurred incidentally during a routine abdominal ultrasonography scan performed in the setting of an episode of suspected cystitis. Subsequent cystoscopy revealed two bulges on the left lateral wall, covered by normal bladder mucosa. The patient was followed up with repeated ultrasonography scans; neither clinical nor radiological alterations were noted until the patient reported an episode of gross haematuria in 2022. Subsequent abdominal CT scan and MRI (Figs 1 and S1) revealed a solid mass, 4.5 cm in maximum size, located near the posterior left bladder wall (in contact with but not infiltrating, the cervix) and another mass measuring 2.1 cm near the left lateral bladder wall.

Operative cystoscopy with biopsy was performed, which caused a hypertensive crisis complicated by acute pulmonary oedema, which required intubation and admission into the intensive care unit. The biopsy specimen's final pathology examination confirmed a bladder paraganglioma.

Further investigations during the hospital stay included a thorough cardiological evaluation (echocardiography, coronary CT-angiography), which suggested an atypical Takotsubo syndrome.

Takotsubo syndrome, also known as stress cardiomyopathy or ‘broken heart syndrome’, is a temporary heart condition that often mimics the symptoms of a heart attack. It is typically triggered by severe emotional or physical stress. The syndrome gets its name from the Japanese word ‘takotsubo’, which means ‘octopus pot’, due to the distinctive shape of the left ventricle seen in imaging tests during the condition [1].

Blood tests (serum chromogranin A, metadrenalines, and normetadrenaline) and urine analysis (urinary metadrenaline and normetadrenaline) revealed elevated levels of chromogranin A and normetadrenaline, while metadrenaline levels remained normal. A whole-body CT scan excluded distant metastases. Positron emission tomography (PET)/CT using gallium-tetraazacyclododecane tetraacetic acid (68Ga-DOTA)-conjugated somatostatin receptor–targeting peptide and 18F-dihydroxyphenylalanine (DOPA) revealed hyper-fixation at the level of the masses, along with two small ileal foci and a right breast nodule (Fig. 2). These extravesical localisations were excluded from being metastatic. Genetic evaluation revealed a succinate dehydrogenase B subunit (SDHB) mutation linked to familial paraganglioma (paraganglioma type PGL4) [2].

After a careful multidisciplinary evaluation, given the masses’ size and the patient's age, the patient was counselled for bladder-sparing robot-assisted laparoscopic surgery (summarised in Video S1).

Prior to the operation, the patient first received alpha-blockade, followed by beta-blockade, and underwent aggressive intravenous fluid resuscitation while being treated in the endocrinology department. The surgery began by placing a left ureteric single-J stent in a retrograde fashion during cystoscopy. The robot-assisted laparoscopic phase started with incising the peritoneum at the level of the vesico-uterine pouch. The bigger mass was identified: its pedicle was first isolated, clipped, and divided. Only after controlling the pedicle was the dissection of the mass carried out. Notwithstanding the additional care, during the dissection of the main mass, a hypertensive crisis occurred (270/150 mmHg) with initial pulmonary oedema. The surgical procedure had to be paused, and the robot had to be undocked for ~10 min to allow for intensive care manoeuvres. The patient was positioned in an anti-Trendelenburg position. Beta-blockers and sodium nitroprusside were administered. The initial response was severe hypotension; however, normal blood pressure values were achieved only after the titration of the nitrate. In the case of nitrates, the titration involves starting with a low dose and gradually increasing it based on the patient's response regarding blood pressure, heart rate, and symptoms until the desired effect is achieved.

Once haemodynamic stability was achieved, the robotic part continued with the completion of the excision of the bigger mass, performed by a combination of extra- and transvesical approaches.

The second smaller mass was identified during the transvesical approach: first, the pedicle was secured. Second, the mass was excised with an extravesical approach. During the excision of the smaller mass, no intraoperative anaesthesiological adverse events occurred. The bladder defect was sutured in a double-layer fashion.

The postoperative course was uneventful. A drain and a Foley catheter were kept in situ for 2 and 10 days, respectively; the ureteric stent was removed after 7 days.

The pathological and immunohistochemical examination revealed a well-differentiated tumour, showing the typical cell-nests, synaptophysin, and chromogranin positive, suggesting paraganglioma (Fig. 3). Genetic analysis revealed mutations of SDHB, which are associated with an aggressive clinical presentation of paraganglioma (and pheochromocytoma).

Urinary bladder paraganglioma is rare, accounting for 0.05% of all bladder neoplasms. Paraganglioma is the denomination of any extra-adrenal pheochromocytoma. It is estimated that ~10% of all pheochromocytomas are extra-adrenal, and ~10% of these occur within the bladder wall. The tumour originates from the chromaffin tissues of the sympathetic nervous system located in the detrusor muscle of the urinary bladder; most commonly, they are located at the dome or the trigone. Paragangliomas can occur at any age, but the mean age at diagnosis is 43 years [3].

They are typically benign, but a variable percentage of cases can be malignant, mostly when associated with hereditary syndromes such as the SDH mutation (familiar paraganglioma syndromes). Malignancy is associated with younger age, larger and multiple masses, and metastases [3].

Signs and symptoms depend on whether the tumour is functional or non-functional. Functional tumours secrete catecholamines (adrenaline and noradrenaline), causing a variety of presenting symptoms (hypertensive crises, headache, palpitations, hot flushes, and sweating). These could also be present only when provoked by micturition (micturition syncope), defecation, sexual activity, ejaculation, or bladder/urethral instrumentation. The most common bladder-specific sign is painless haematuria, although it is non-specific. Biochemistry plays a key role in functional tumours: plasma and urine catecholamines and metadrenalines (more sensitive and specific) levels are usually elevated. Chromogranin A is also often elevated [3].

The primary tumour is usually diagnosed through cross-sectional imaging (either CT or MRI): common findings at MRI are a well-circumscribed round vascularised lesion that is hyperintense in T2 (‘lightbulb sign’). The best PET/CT imaging for diagnosing paragangliomas is typically 68Ga-DOTA-conjugated somatostatin receptor-targeting peptide. This imaging technique uses gallium-68 labelled with DOTA-Tyr3-octreotate, a somatostatin analogue. It targets somatostatin receptors, often overexpressed in neuroendocrine tumours, including paragangliomas. While 68Ga-DOTA PET/CT is highly regarded, other imaging techniques such as 18F-fluorodeoxyglucose (FDG) PET/CT and 131I-metaiodobenzylguanidine (MIBG) scintigraphy may still be used in specific scenarios: 18F-FDG PET/CT is useful for paragangliomas that do not express somatostatin receptors; however, it is less effective for small, indolent tumours; 131I-MIBG scintigraphy is primarily indicated for pheochromocytomas, but can also be used for paragangliomas that uptake MIBG. Unfortunately, it may miss non-functioning paragangliomas or those not taking up MIBG [4].

Cystoscopy, when performed, shows normal mucosa and an underlying mass bulging it. Transurethral manipulation and biopsy of functional paragangliomas could lead to potentially life-threatening cardiac events due to massive catecholamine release. This was the case of the first interventional cystoscopy performed at another institution before the patient came to us.

For the same reason, an endoscopic, transurethral approach as a treatment option should be avoided. As such, it often leads to incomplete resection and a high risk of perioperative cardiac events, particularly when a correct histopathological or clinical diagnosis has yet to be made [5]. Moreover, the endoscopic approach lacks the control of the vascular pedicle of the mass that a surgical approach (either open, laparoscopic, or robot-assisted) guarantees.

For these medical reasons, preoperative care is fundamental. About 2 weeks before surgery, alpha-blockade should be started, preferably with an irreversible alpha-blocker such as phenoxybenzamine. This molecule irreversibly binds to the alpha receptors, rendering any potential intraoperative catecholamine release from tumour manipulation ‘harmless’, as it would require de novo synthesis of alpha receptors for the catecholamines to exert their effect. Beta-blockade should be introduced (mainly to treat side effects from alpha-blockade) only after reaching the appropriate alpha-blockade. Otherwise, it would increase the affinity of catecholamines for the α1 receptors. Finally, 1–2 days before surgery, aggressive intravenous hydration to restore the intravascular volume should be initiated to avoid postoperative severe hypotension given the prolonged effect of alpha-blockade [6].

After proper preparation, surgical excision is the mainstay treatment because paraganglioma is chemo-radioresistant. A radical excision of the mass should be performed whenever feasible. This is usually achieved through a partial cystectomy. Indeed, the bladder mucosa at the base of the mass should always be removed. In selected cases (large masses, metastases, suspected malignancy), radical cystectomy can be indicated. Pelvic lymph node dissection should be performed when a radical cystectomy is indicated, although there is not sufficient evidence supporting this choice [7].

Histopathological examination shows polygonal cells arranged in a nested fashion (‘Zellballen’), surrounded by a fibrovascular matrix [8]. This pattern could trick the pathologist's eye and be confused with a nested variant of TCC. Immunohistochemistry shows positivity for chromogranin A, synaptophysin, and GATA binding protein 3 (GATA-3); cytokeratins are negative [3].

A summation section of the most relevant diagnostic evaluation, medical, and anaesthesiological information is provided as Data S1 at the reader's convenience.

In summary, our case report underscores that not all patients with gross haematuria should be treated equally. Specifically, the presence of a mass bulging on the bladder mucosa in a younger patient with adrenergic symptoms should suggest at least considering the possibility of a bladder paraganglioma. This could help reach a correct diagnosis before any invasive manoeuvre is performed. Moreover, it would avoid potentially fatal perioperative adverse events or incomplete excision of the mass typical of transurethral resections performed before confirming paraganglioma diagnosis [9].

Once surgical removal of a diagnosed bladder paraganglioma is indicated, despite cautious premedication of patients, the experience of the surgeon, and necessary surgical precautions in handling these formations before controlling their vascular pedicles, it must be remembered that surgery is not straightforward when such paragangliomas are functional. This holds true both from a technical standpoint and, more importantly, considering its potential anaesthesiological implications.

The authors have no conflict of interest.

Abstract Image

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
意大利维罗纳大学的 "本月病例"--应对膀胱副神经节瘤的内外科挑战:临床病例的启示
一名44岁的女性前来就诊,她有两个膀胱旁肿物的病史,通过放射成像监测了10年。患者的病史显示,自22岁以来,骨科手术后多次发作肺栓塞。病人的凝血功能检查呈阴性。值得注意的是,患者在年轻时患有高血压,需要多种药物治疗,并伴有额外的肾上腺素能症状,如潮红、肢体震颤、惊恐发作和心悸。膀胱肿块的第一个诊断偶然发生在例行腹部超声扫描的设置设置一个疑为膀胱炎。随后的膀胱镜检查显示左侧壁有两个凸起,被正常膀胱粘膜覆盖。对患者进行反复超声扫描随访;直到2022年患者报告出现肉眼血尿,才发现临床和影像学改变。随后的腹部CT扫描和MRI(图1和S1)显示一个实性肿块,最大尺寸为4.5 cm,位于左侧膀胱后壁附近(与子宫颈接触但未浸润),另一个肿块位于左侧膀胱外壁附近,尺寸为2.1 cm。手术膀胱镜检查和活检导致高血压危象并急性肺水肿,需要插管并进入重症监护病房。活检标本的最终病理检查证实为膀胱副神经节瘤。住院期间的进一步检查包括全面的心脏病学评估(超声心动图、冠状动脉ct血管造影),提示非典型Takotsubo综合征。Takotsubo综合征,也被称为应激性心肌病或“心碎综合征”,是一种暂时的心脏疾病,通常会模仿心脏病发作的症状。它通常由严重的情绪或身体压力引发。这种综合症的名字来源于日语“takotsubo”,意思是“章鱼锅”,因为在[1]的情况下,在成像测试中可以看到左心室的独特形状。血液检查(血清嗜铬粒蛋白A、甲肾上腺素和去甲肾上腺素)和尿液分析(尿中甲肾上腺素和去甲肾上腺素)显示嗜铬粒蛋白A和去甲肾上腺素水平升高,而甲肾上腺素水平保持正常。全身CT扫描排除远处转移。使用镓-四氮杂环十二烷四乙酸(68Ga-DOTA)偶联生长抑素受体靶向肽和18f -二羟基苯基丙氨酸(DOPA)的正电子发射断层扫描(PET)/CT显示肿块水平超固定,以及两个小回肠灶和一个右乳房结节(图2)。这些体外定位被排除为转移性。遗传评估显示琥珀酸脱氢酶B亚基(SDHB)突变与家族副神经节瘤(副神经节瘤型PGL4)[2]有关。经过仔细的多学科评估,考虑到肿块的大小和患者的年龄,建议患者进行保留膀胱的机器人辅助腹腔镜手术(视频S1总结)。手术前,患者首先接受α -阻断治疗,随后接受β -阻断治疗,并在内分泌科接受积极的静脉输液复苏。手术开始时,在膀胱镜检查期间逆行放置左侧输尿管单j型支架。机器人辅助腹腔镜阶段开始于在膀胱子宫袋水平切开腹膜。确定较大的肿块:首先将其蒂分离、剪断并分离。只有控制了椎弓根后,才进行肿块的解剖。尽管进行了额外的治疗,但在剥离主要肿块期间,出现了高血压危象(270/150 mmHg),并伴有初始肺水肿。手术过程必须暂停,机器人必须断开约10分钟,以便进行重症监护操作。将患者置于反trendelenburg位。给予-受体阻滞剂和硝普钠。最初的反应是严重低血压;然而,只有在硝酸滴定后才达到正常的血压值。在硝酸盐的情况下,滴定包括从低剂量开始,并根据患者对血压、心率和症状的反应逐渐增加剂量,直到达到预期的效果。一旦血流动力学稳定,机器人部分继续完成更大肿块的切除,通过膀胱外入路和经膀胱入路的结合进行。第二个较小的肿块是在经膀胱入路时发现的:首先,将椎弓根固定。其次,肿块采用体外入路切除。在小肿块切除过程中,未发生术中麻醉不良事件。 膀胱缺损采用双层缝合。术后过程平淡无奇。引流管和Foley导管分别放置2天和10天;7天后取出输尿管支架。病理和免疫组织化学检查显示肿瘤分化良好,显示典型的细胞巢、突触素和嗜铬粒蛋白阳性,提示副神经节瘤(图3)。遗传分析显示SDHB突变,这与副神经节瘤(和嗜铬细胞瘤)的侵袭性临床表现有关。膀胱副神经节瘤是一种罕见的肿瘤,占所有膀胱肿瘤的0.05%。副神经节瘤是任何肾上腺外嗜铬细胞瘤的名称。据估计,约10%的嗜铬细胞瘤发生在肾上腺外,约10%发生在膀胱壁内。肿瘤起源于位于膀胱逼尿肌的交感神经系统的嗜铬组织;最常见的是,它们位于圆顶或三角区。副神经节瘤可发生于任何年龄,但诊断时的平均年龄为43岁。它们通常是良性的,但也有不同比例的病例可能是恶性的,主要是与遗传综合征如SDH突变(常见的副神经节瘤综合征)有关。恶性肿瘤与较年轻、较大和多发肿块以及转移有关。体征和症状取决于肿瘤是功能性还是非功能性。功能性肿瘤分泌儿茶酚胺(肾上腺素和去甲肾上腺素),引起各种症状(高血压危象、头痛、心悸、潮热和出汗)。这些症状也可能仅在排尿(排尿晕厥)、排便、性行为、射精或膀胱/尿道器械引起时出现。最常见的膀胱特异性征象是无痛性血尿,尽管它是非特异性的。生物化学在功能性肿瘤中起关键作用:血浆和尿液儿茶酚胺和甲肾上腺素(更敏感和特异性)水平通常升高。嗜铬粒蛋白A也常升高。原发性肿瘤通常通过横断成像(CT或MRI)诊断:MRI的常见表现是界限清楚的圆形血管病变,T2呈高强度(“灯泡征”)。诊断副神经节瘤的最佳PET/CT影像通常是68ga - dota偶联生长抑素受体靶向肽。这种成像技术使用了带有DOTA-Tyr3-octreotate(一种生长抑素类似物)标记的镓-68。它靶向生长抑素受体,通常在神经内分泌肿瘤中过度表达,包括副神经节瘤。虽然68Ga-DOTA PET/CT受到高度重视,但其他成像技术,如18f -氟脱氧葡萄糖(FDG) PET/CT和131i -间氧苄基胍(MIBG)显像仍可用于特定情况:18F-FDG PET/CT对不表达生长抑素受体的副神经节瘤有用;然而,它对小的惰性肿瘤效果较差;131I-MIBG显像主要用于嗜铬细胞瘤,但也可用于摄取MIBG的副神经节瘤。不幸的是,它可能会遗漏无功能的副神经节瘤或不接受MIBG[4]的副神经节瘤。膀胱镜检查显示正常粘膜和一个隆起的肿块。由于大量儿茶酚胺释放,经尿道操作和功能性副神经节瘤活检可能导致潜在的危及生命的心脏事件。这是第一次介入膀胱镜检查的情况下,在另一个机构进行之前,病人来我们这里。出于同样的原因,应避免内窥镜,经尿道入路作为治疗选择。因此,它经常导致不完全切除和围手术期心脏事件的高风险,特别是在正确的组织病理学或临床诊断尚未做出的情况下。此外,内窥镜入路缺乏手术入路(开放、腹腔镜或机器人辅助)所保证的对肿瘤血管蒂的控制。由于这些医学原因,术前护理是至关重要的。手术前2周左右,应开始使用α阻断剂,最好使用不可逆α阻断剂,如苯氧苄胺。这种分子不可逆地与α受体结合,使得任何可能在手术中因肿瘤处理而释放的儿茶酚胺都是“无害的”,因为儿茶酚胺需要重新合成α受体才能发挥作用。只有在达到适当的α阻断后才应引入β阻断剂(主要用于治疗α阻断剂的副作用)。否则会增加儿茶酚胺对α1受体的亲和力。最后,在手术前1-2天,应开始积极静脉补水以恢复血管内容量,以避免术后严重低血压,因为α -阻断剂[6]的作用延长。 经过适当的准备,手术切除是主要的治疗方法,因为副神经节瘤是化疗放射耐药的。只要可行,就应对肿瘤进行根治性切除。这通常通过部分膀胱切除术来实现。确实,在肿块底部的膀胱粘膜应该被切除。在某些情况下(大肿块、转移、疑似恶性肿瘤),可行根治性膀胱切除术。当需要行根治性膀胱切除术时,应行盆腔淋巴结清扫术,尽管没有足够的证据支持这一选择。组织病理学检查显示多边形细胞呈巢状排列(“Zellballen”),被纤维血管基质[8]包围。这种模式可能会欺骗病理学家的眼睛,并与嵌套的TCC变体混淆。免疫组化示嗜铬粒蛋白A、突触素、GATA结合蛋白3 (GATA-3)阳性;细胞角蛋白呈负[3]。最相关的诊断评估、医学和麻醉信息的总结部分作为数据S1提供给读者方便。总之,我们的病例报告强调并不是所有的血尿患者都应该得到平等的治疗。具体来说,在有肾上腺素能症状的年轻患者膀胱粘膜出现肿块时,至少应考虑膀胱副神经节瘤的可能性。这有助于在进行任何侵入性手术之前做出正确的诊断。此外,它将避免潜在的致命围手术期不良事件或在确认副神经节瘤诊断之前经尿道切除典型肿块的不完全切除。一旦确诊的膀胱副神经节瘤需要手术切除,尽管患者有谨慎的药物治疗,外科医生的经验,以及在控制血管蒂之前处理这些形成的必要的手术预防措施,但必须记住,当这种副神经节瘤具有功能时,手术并不是直截了当的。从技术角度来看,更重要的是,考虑到其潜在的麻醉意义,这一点是正确的。作者没有利益冲突。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BJU International
BJU International 医学-泌尿学与肾脏学
CiteScore
9.10
自引率
4.40%
发文量
262
审稿时长
1 months
期刊介绍: BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.
期刊最新文献
Beyond sensitivity: artificial intelligence and micro-ultrasonography in prostate cancer detection. Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future? Deep early tumour shrinkage in metastatic upper tract urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab. Characteristics and outcomes of men presenting with complications of metastatic prostate cancer. Response to Lin et al.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1